Ms. Carolyn A Yaffe, MSW, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 172 Ashmont St, Dorchester Center, MA 02124 Phone: 617-823-3054 |
Ms. Donna A Bertolotti, MTS, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 67 Semont Rd, 1st Floor, Dorchester Center, MA 02124 Phone: 617-448-0380 |
Shelana Angela Simon Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 63 Fairmount St, Dorchester Center, MA 02124 Phone: 617-506-0674 |
Ms. Arona M Bauer, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 80 Lonsdale St # 3, Dorchester Center, MA 02124 Phone: 617-257-3437 |
Mrs. Shannon Broverman Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-296-4012 Fax: 617-474-3832 |
Olivia M Apollon, MSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 637 Washington St, Dorchester Center, MA 02124 Phone: 617-825-9660 Fax: 617-822-8418 |
Ms. Elizabeth A Morris, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 2100 Dorchester Ave, Dorchester Center, MA 02124 Phone: 617-296-4012 Fax: 617-474-3853 |
Michael Lodge Jr., MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 34 Fairmount St, Dorchester Center, MA 02124 Phone: 617-669-5589 |
News Archive
Doctors know patients with atrial fibrillation are at a higher risk of having a stroke, and now a new study finds that integrating two separate clinical risk score models helps clinicians more accurately assess the stroke risk of patients with Afib.
Basil can protect against the harmful effects of ageing, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.
Scientists have discovered that cancer-causing genetic mutations have better-disguised electronic signatures than other mutations - a trait which could help them fly under the radar of the body's defence mechanisms.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.
New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors' intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.
› Verified 9 days ago